Synairgen shares rise over 450% as COVID-19 drug has huge potential

The FINANCIAL — Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19…

6 mins read